Drug Profile


Alternative Names: PRX-00023

Latest Information Update: 19 Feb 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator EPIX Pharmaceuticals
  • Developer EPIX Pharmaceuticals; National Institute of Neurological Disorders and Stroke; Proximagen
  • Class Antidepressants; Anxiolytics; Piperazines; Small molecules; Sulfonamides
  • Mechanism of Action Serotonin 1A receptor agonists; Sigma-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epilepsy
  • Discontinued Drug-induced dyskinesia; Generalised anxiety disorder; Major depressive disorder

Most Recent Events

  • 14 Aug 2012 Proximagen has been acquired by Upsher-Smith
  • 05 Mar 2012 Discontinued - Phase-I for Drug-induced dyskinesia in USA (PO)
  • 27 Jan 2011 Phase-II clinical trials in Epilepsy in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top